NCI-H2170Homo sapiens (Human)Cancer cell line

Also known as: NCIH2170, H-2170, H2170

🤖 AI SummaryBased on 13 publications

Quick Overview

Human cancer cell line with potential for drug sensitivity studies

Detailed Summary

The NCI-H2170 cell line is a human-derived cancer cell line that has been utilized in various cancer research studies. It is part of a comprehensive collection of cell lines used for understanding the molecular mechanisms of cancer and developing targeted therapies. Research on this cell line has contributed to the identification of key pathways and potential therapeutic targets in cancer, particularly in the context of small cell lung cancer (SCLC) and other malignancies. The cell line's genetic and molecular profiles have been analyzed to understand its response to different therapeutic agents, making it a valuable resource for preclinical drug development and personalized medicine approaches.
Generated on 6/17/2025

Basic Information

Database IDCVCL_1535
SpeciesHomo sapiens (Human)

Donor Information

Age CategoryUnknown
SexMale

Disease Information

DiseaseLung squamous cell carcinoma
LineageLung
SubtypeLung Squamous Cell Carcinoma
OncoTree CodeLUSC

DepMap Information

Source TypeATCC
Source IDACH-000481_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg158Gly (c.472C>G)Unspecified-Unknown
MutationSimpleRHOAp.Gly17Val (c.50G>T)Unspecified-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
9
D16S539
12,14
D18S51
13,14
D19S433
13.2,14
D21S11
31.2
D2S1338
17,24
D3S1358
19
D5S818
12
D7S820
10
D8S1179
14
FGA
25,26
Penta D
9
Penta E
7,13
TH01
8,9.3
TPOX
8,9
vWA
15,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

Br. J. Cancer 109:1599-1608(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.

Gazdar A.F., Lam S., MacAulay C., Lam W.L.

Int. J. Cancer 118:1556-1564(2006).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).